MK886 Inhibits the Proliferation of HL-60 Leukemia Cells by Suppressing the Expression of Mpges-1 and Reducing Prostaglandin E2 Synthesis

YiQing Li,SongMei Yin,DaNian Nie,ShuangFeng Xie,LiPing Ma,XiuJu Wang,YuDan Wu,Jie Xiao
DOI: https://doi.org/10.1007/s12185-011-0954-0
2011-01-01
International Journal of Hematology
Abstract:Microsomal prostaglandin E synthase-1 (mPGES-1), an inducible enzyme that specifically catalyzes the conversion of prostaglandin H2 (PGH2) to prostaglandin E2 (PGE2), has been reported to be over-expressed in a variety of solid tumor cells and tissues, but not in normal tissues. Its association with leukemia, however, has not been fully investigated. Our study revealed, for the first time, that mPGES-1 is over-expressed in human acute myeloid leukemia HL-60 cells. Cytotoxicity assays and flow cytometry showed that MK886, an inhibitor of mPGES-1, inhibits proliferation of HL-60 cells and induces apoptosis in a dose- and time-dependent manner, which may result from down-regulation of mPGES-1 expression and PGE2 synthesis. Evaluation of mediators of apoptotic signaling revealed up-regulation of BAX expression and caspase-3 activity, as well as significant decreases in Bcl2 and P-Akt. We conclude that MK886 reduces the viability of leukemia HL-60 cells by reducing mPGES-1 expression and PGE2 synthesis in a dose-dependent manner, which strongly suggests that mPGES-1 inhibitors should be considered as promising candidates for leukemia treatment.
What problem does this paper attempt to address?